Kura Oncology (KURA) and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer.
Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies.
It will also be eligible for $741 million on achieving development, regulatory and commercial milestones, the companies added.
Under the agreement, the companies will jointly develop and commercialize the drug in the US, while Kyowa Kirin will hold exclusive commercialization rights outside the US.
Kura stock fell 15% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.